My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()

    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0919
    CAS #: 134308-13-7Purity ≥98%

    Description: Tolcapone (also known as Ro 40-7592) is a novel, selective, potent, reversible, orally-bioavailable small-molecule inhibitor of catechol-O-methyl transferase (COMT) with Ki of 30 NM. Tolcapone is used as an adjunct to levodopa therapy for the treatment of Parkinson’s disease (PD). The chemical structure of tolcapone contains a catechol structure with two electron withdrawing groups that can easily deliver a proton resulting in an anion that has high affinity for COMT.

    References: Adv Neurol. 1990;53:497-503; Br J Pharmacol. 1996 Feb;117(3):516-520.

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Citation of InvivoChem Larotrectinib (V2599) by Cell (2020) 183(5):1202-1218.e25
    • Citation of InvivoChem BMH-21 (V1435) by Cell Stem Cell 2020, 26(6): 845-861.e12.
    • Citation of InvivoChem BMS-582949 (V2668) by Cells 2020, 9(6):1472. doi: 10.3390/cells90614
    • Citation of InvivoChem Resveratrol (V0430) by Arterioscler Thromb Vasc Biol 2020; ATVBAHA12
    • Citation of InvivoChem venetoclax and S63845 (V2797) by Cell Death and Disease (2020) 11:316.
    • Citation of InvivoChem Belumosudil (KD025) by Am J Physiol Renal Physiol. 2019; 317(4):F839-F851.
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)273.24
    CAS No.134308-13-7
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 55 mg/mL (201.3 mM)
    Water: <1 mg/mL
    Ethanol: 55 mg/mL (201.3 mM)
    Other info

    Chemical Name: (3,4-dihydroxy-5-nitrophenyl)-(4-methylphenyl)methanone


    InChi Code: InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3

    SMILES Code: O=C(C1=CC([N+]([O-])=O)=C(O)C(O)=C1)C2=CC=C(C)C=C2           

    SynonymsSOM0226; Ro 40 7592; Tolcapone, Tasmar, Ro 40-7592; Ro-40-7592; SOM-0226; SOM 0226; 

    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      • V1
      • C2
      • V2
    In Vitro

    In vitro activity: A 922500 inhibits the phylogenetic family members acyl coenzyme A cholesterol acyltransferase-1 and -2 with IC50 of 296 μM. A 922500 potently inhibits huDGAT-1 and mseDGAT-1.

    Kinase Assay: COMT activity was evaluated by the ability of homogenates to methylate adrenaline to metanephrine. Aliquots of 0.5 ml of the homogenate were preincubated for 20 min with 0.5 ml of phosphate buffer (0.5 mM); thereafter, the reaction mixture was incubated for 30 min with increasing concentrations of adrenaline (5 to 500 uM) in the presence of a saturating concentration (100 /M) of the methyl donor (S-adenosyl-L-methionine); the incubation medium contained also pargyline (100 gM), MgCl2 (100 gM) and EGTA (1 mM). The preincubation and incubation were carried out at 37°C, in conditions of light protection, with continuous shaking and without oxygenation. In experiments conducted with the aim of studying the inhibitory effect of tolcapone on COMT activity, tissue homogenates were preincubated for 15 min with increasing concentrations of tolcapone (0.5 to 10,000 nM); the incubation was performed in the presence of a concentration of adrenaline three times the corresponding Km value, as determined in saturation experiments for each age group. At the end of the incubation period the tubes were transferred to ice and the reaction was stopped by the addition of 100 ul of perchloric acid (2 M). The samples were then centrifuged (200 g, 4 min, 4C), and 500 Ml aliquots of the supernatant filtered on Millipore microfilters (MF1) were used for the assay of metanephrine. This procedure allows 99% extraction of catecholamines and their methylated metabolites.

    Cell Assay: Tolcapone as an inhibitor of COMT shows a protective effect against HIV associated dendritic and synaptic damage.

    In VivoZucker fatty rats and diet-induced dyslipidemic hamsters are dosed orally with A 922500 (0.03, 0.3, and 3 mg/kg) for 14 days. Serum triglycerides ae significantly reduced by the 3 mg/kg dose of A 922500 in both the Zucker fatty rat (39%) and hyperlipidemic hamster (53%). These serum triglyceride changes are accompanied by significant reductions in free fatty acid levels by 32% in the Zucker fatty rat and 55% in the hyperlipidemic hamster. In addition, high-density lipoprotein-cholesterol is significantly increases (25%) in the Zucker fatty rat by A 922500 administered at 3 mg/kg. A 922500 confers weight loss and a reduction in liver triglycerides when dosed chronically in DIO mice and depletes serum triglycerides following a lipid challenge in a dose-dependent manner, thus, reproducing major phenotypical characteristics of DGAT-1(-/-) mice. A 922500 (0.03, 0.3 and 3 mg/kg, p.o.) dose-dependently attenuates the maximal postprandial rise in serum triglyceride concentrations.
    Animal modelMale Golden Syrian hamsters with hyperlipidemia, and Male Zucker fatty rats
    Formulation & DosageDissolved in Polyethylene glycol/hydroxypropyl-β-cyclodextrin (10% w/v); 0.03, 0.3, and 3 mg/kg; oral gavage

    Adv Neurol. 1990;53:497-503; Br J Pharmacol. 1996 Feb;117(3):516-520; Neurology. 1992 Mar;42(3 Pt 1):683-5; J Neural Transm Suppl. 1990;32:375-80.

    These protocols are for reference only. InvivoChem does not independently validate these methods.


    Tolcapone and tafamidis effects over WT, V122I-TTR and A25T-TTR aggregation and stability. Nat Commun. 2016; 7: 10787.


    Interaction of TTR with tolcapone assessed by ITC. Nat Commun. 2016; 7: 10787.


    Tolcapone is orally available and stabilizes TTR in humans and in transgenic mice expressing the amyloidogenic human V30M-TTR variant. Nat Commun. 2016; 7: 10787.


      Home Prev Next Last page / pices


      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      Do you confirm the receipt?